Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 15/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590892 | 0.90 | OPRM1 (0.38) | OPRM1OPRD1OPRK1 | |
| SCHEMBL3598241 | 0.85 | OPRM1 (0.40) | OPRM1OPRD1OPRK1NPC1 | |
| SCHEMBL3598071 | 0.83 | POLB (0.35) | — | |
| SCHEMBL3598784 | 0.78 | ADRB2 (0.40) | OPRM1OPRD1OPRK1 | |
| SCHEMBL2210725 | 0.77 | ADRB2 (0.41) | — | |
| SCHEMBL3597011 | 0.76 | SMYD2 (0.51) | NPC1 | |
| SCHEMBL3593752 | 0.76 | OPRM1 (0.47) | OPRM1OPRD1OPRK1 | |
| SCHEMBL2213045 | 0.76 | ADRB2 (0.41) | — | |
| SCHEMBL3598105 | 0.75 | OPRM1 (0.40) | OPRM1OPRD1OPRK1 | |
| SCHEMBL3592200 | 0.75 | ADRB2 (0.37) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | OPRM1 83/4885OPRD1 38/4885OPRK1 76/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | OPRM1 51/4885OPRD1 27/4885OPRK1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.